Kymera therapeutics announces three scientific presentations at the eortc-nci-aacr 2024 symposium

Watertown, mass., oct. 23, 2024 (globe newswire) -- kymera therapeutics, inc. (nasdaq: kymr), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (tpd), today announced that new preclinical data from its innovative tpd platform will be presented across three poster presentations at the eortc-nci-aacr symposium on molecular targets and cancer therapeutics being held october 23-25, 2024, in barcelona, spain. the presentations include new data on its preclinical biomarker-based approach for kt-253, its mdm2 degrader.
NCI Ratings Summary
NCI Quant Ranking